Discontinued ProductUnfortunately 6-Chlorokynurenic acid (Cat. No. 0287) has been withdrawn from sale for commercial reasons.
Reported to have quisqualate receptor antagonist activity.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
References are publications that support the products' biological activity.
View Related Products by Product Action
Keywords: 6-Chlorokynurenic acid, supplier, Non-selective, Ionotropic, Glutamate, Non-selective, Ionotropic, Glutamate, Tocris Bioscience
Citations for 6-Chlorokynurenic acid
Citations are publications that use Tocris products.
Currently there are no citations for 6-Chlorokynurenic acid.
Reviews for 6-Chlorokynurenic acid
There are currently no reviews for this product. Be the first to review 6-Chlorokynurenic acid and earn rewards!
Have you used 6-Chlorokynurenic acid?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.